Compare iShares MSCI Germany (DAX) (EWG) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Germany (DAX) vs Revvity Inc — how do they compare? iShares MSCI Germany (DAX) trades at $40.96 (market cap $1.42B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 12× iShares MSCI Germany (DAX)'s market cap, and Revvity Inc pays a 0.18% dividend while iShares MSCI Germany (DAX) pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Germany (DAX) for 54 Days and Revvity Inc for 12 Days on average.
| EWG | RVTY | |
|---|---|---|
Market Cap | $1.42B | $16.98B |
Volume | 1,110,573 | 1,456,900 |
Sector | Broad Market / Factor | Health |
52-Week High | $44.59 | $157.36 |
52-Week Low | $38.08 | $82.26 |
Typical Hold Time | 54 Days | 12 Days |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWG is trading at $40.67, down 0.59% with a bearish technical outlook as moving averages and oscillators signal selling pressure. The stock faces resistance at $41 with support at $40. Recent European market news highlights ECB rate hikes and energy price concerns affecting regional equities, though some analysts note resilience in European stocks despite macroeconomic pressures.
The bearish technical indicators and European economic uncertainty create near-term headwinds. Investment opportunity exists if the stock holds above $40 support, but risks include further ECB tightening and energy-driven inflation. Upside potential requires breaking above $41 resistance with improved market sentiment toward European equities.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
